Unlocking the quiet zone: The small airway asthma phenotype

The Lancet Respiratory Medicine

Volumn 2, Issue 6, 2014, Pages 497-506

  Lipworth, Brian ^a   Manoharan, Arvind ^a   Anderson, William ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LONG ACTING DRUG; NITRIC OXIDE; PREDNISOLONE; ANTIASTHMATIC AGENT;

ADD ON THERAPY; AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ASTHMA; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY POWDER INHALER; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMPULSE OSCILLOMETRY; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; NOTE; OSCILLOMETRY; PARTICLE SIZE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RESIDUAL VOLUME; RESPIRATORY TRACT INFLAMMATION; SEVERE PERSISTENT ASTHMA; SMALL AIRWAY ASTHMA; SMALL AIRWAY DISEASE; SPIROMETRY; BRONCHUS; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHI; FORCED EXPIRATORY VOLUME; HUMANS; PHENOTYPE;

EID: 84901787746     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70103-1     Document Type: Note

References (63)

1. Macklem PT, Mead J Resistance of central and peripheral airways measured by a retrograde catheter. J Appl Physiol 1967, 22:395-401.
2. Mead J The lung's "quiet zone". N Engl J Med 1970, 282:1318-1319.
3. Wagner EM, Bleecker ER, Permutt S, Liu MC Direct assessment of small airways reactivity in human subjects. Am J Respir Crit Care Med 1998, 157:447-452.
4. van der Wiel E, ten Hacken NH, Postma DS, van den Berge M Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol 2013, 131:646-657.
5. Hamid Q Pathogenesis of small airways in asthma. Respiration 2012, 84:4-11.
6. Verbanck S Physiological measurement of the small airways. Respiration 2012, 84:177-188.
7. Dubois AB, Brody AW, Lewis DH, Burgess BF Oscillation mechanics of lungs and chest in man. J Appl Physiol 1956, 8:587-594.
8. Oostveen E, MacLeod D, Lorino H, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 2003, 22:1026-1041. for the ERS Task Force on Respiratory Impedance Measurements.
9. LaPrad AS, Lutchen KR Respiratory impedance measurements for assessment of lung mechanics: focus on asthma. Respir Physiol Neurobiol 2008, 163:64-73.
10. Anderson WJ, Zajda E, Lipworth BJ Are we overlooking persistent small airways dysfunction in community-managed asthma?. Ann Allergy Asthma Immunol 2012, 109:185-189.
11. Boudewijn IM, Telenga ED, van der Wiel E, et al. Less small airway dysfunction in asymptomatic bronchial hyperresponsiveness than in asthma. Allergy 2013, 68:1419-1426.
12. Tgavalekos NT, Musch G, Harris RS, et al. Relationship between airway narrowing, patchy ventilation and lung mechanics in asthmatics. Eur Respir J 2007, 29:1174-1181.
13. Downie SR, Salome CM, Verbanck S, Thompson B, Berend N, King GG Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway inflammation. Thorax 2007, 62:684-689.
14. Shi Y, Aledia AS, Tatavoosian AV, Vijayalakshmi S, Galant SP, George SC Relating small airways to asthma control by using impulse oscillometry in children. J Allergy Clin Immunol 2012, 129:671-678.
15. Shi Y, Aledia AS, Galant SP, George SC Peripheral airway impairment measured by oscillometry predicts loss of asthma control in children. J Allergy Clin Immunol 2013, 131:718-723.
16. Rao DR, Gaffin JM, Baxi SN, Sheehan WJ, Hoffman EB, Phipatanakul W The utility of forced expiratory flow between 25% and 75% of vital capacity in predicting childhood asthma morbidity and severity. J Asthma 2012, 49:586-592.
17. Bourdin A, Paganin F, Préfaut C, Kieseler D, Godard P, Chanez P Nitrogen washout slope in poorly controlled asthma. Allergy 2006, 61:85-89.
18. Thompson BR, Douglass JA, Ellis MJ, et al. Peripheral lung function in patients with stable and unstable asthma. J Allergy Clin Immunol 2013, 131:1322-1328.
19. Farah CS, King GG, Brown NJ, et al. The role of the small airways in the clinical expression of asthma in adults. J Allergy Clin Immunol 2012, 129:381-387.
20. Farah CS, King GG, Brown NJ, Peters MJ, Berend N, Salome CM Ventilation heterogeneity predicts asthma control in adults following inhaled corticosteroid dose titration. J Allergy Clin Immunol 2012, 130:61-68.
21. Sonnappa S, Bastardo CM, Saglani S, Bush A, Aurora P Relationship between past airway pathology and current lung function in preschool wheezers. Eur Respir J 2011, 38:1431-1436.
22. in 't Veen JC, Beekman AJ, Bel EH, Sterk PJ Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 2000, 161:1902-1906.
23. Mahut B, Peiffer C, Bokov P, Beydon N, Delclaux C Gas trapping is associated with severe exacerbation in asthmatic children. Respir Med 2010, 104:1230-1233.
24. Mahut B, Delacourt C, Zerah-Lancner F, De Blic J, Harf A, Delclaux C Increase in alveolar nitric oxide in the presence of symptoms in childhood asthma. Chest 2004, 125:1012-1018.
25. Puckett JL, Taylor RW, Leu SY, et al. Clinical patterns in asthma based on proximal and distal airway nitric oxide categories. Respir Res 2010, 11:47.
26. Gonem S, Natarajan S, Desai D, et al. Clinical significance of small airway obstruction markers in patients with asthma. Clin Exp Allergy 2014, 44:499-507.
27. Verbanck S, Schuermans D, Vincken W Inflammation and airway function in the lung periphery of patients with stable asthma. J Allergy Clin Immunol 2010, 125:611-616.
28. Condorelli P, Shin HW, Aledia AS, Silkoff PE, George SC A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. J Appl Physiol (1985) 2007, 102:417-425.
29. Paraskakis E, Brindicci C, Fleming L, et al. Measurement of bronchial and alveolar nitric oxide production in normal children and children with asthma. Am J Respir Crit Care Med 2006, 174:260-267.
30. Mahut B, Delclaux C, Tillie-Leblond I, et al. Both inflammation and remodeling influence nitric oxide output in children with refractory asthma. J Allergy Clin Immunol 2004, 113:252-256.
31. Gelb AF, George SC, Silkoff PE, et al. Central and peripheral airway/alveolar sites of exhaled nitric oxide in acute asthma. Thorax 2010, 65:619-625.
32. Yamaguchi M, Niimi A, Ueda T, et al. Effect of inhaled corticosteroids on small airways in asthma: investigation using impulse oscillometry. Pulm Pharmacol Ther 2009, 22:326-332.
33. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999, 104:1215-1222.
34. Manoharan A, Anderson WJ, Lipworth BJ Relationship of large and small airway response with inhaled corticosteroid to asthma control. Ann Allergy Asthma Immunol 2013, 111:140-142.
35. Verbanck S, Schuermans D, Paiva M, Vincken W The functional benefit of anti-inflammatory aerosols in the lung periphery. J Allergy Clin Immunol 2006, 118:340-346.
36. Goldin JG, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999, 104:S258-S267.
37. Tunon-de-Lara JM, Laurent F, Giraud V, et al. Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. J Allergy Clin Immunol 2007, 119:583-590.
38. Leach CL, Kuehl PJ, Chand R, Ketai L, Norenberg JP, McDonald JD Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol 2012, 108:195-200.
39. Nicolini G, Chetta A, Simonazzi A, Tzani P, Aiello M, Olivieri D Both bronchial and alveolar exhaled nitric oxide are reduced with extrafine beclomethasone dipropionate in asthma. Allergy Asthma Proc 2010, 31:85-90.
40. Scichilone N, Battaglia S, Taormina S, Modica V, Pozzecco E, Bellia V Alveolar nitric oxide and asthma control in mild untreated asthma. J Allergy Clin Immunol 2013, 131:1513-1517.
41. Scichilone N, Battaglia S, Bellia V Reply: to PMID 23639306. J Allergy Clin Immunol 2013, 132:1256.
42. Robroeks CM, van de Kant KD, van Vliet D, et al. Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone vs fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma. Ann Allergy Asthma Immunol 2008, 100:601-607.
43. Berry M, Hargadon B, Morgan A, et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J 2005, 25:986-991.
44. Williamson PA, Short PM, Vaidyanathan S, Lipworth BJ Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add-on therapy. Br J Clin Pharmacol 2013, 75:93-102.
45. Thongngarm T, Silkoff PE, Kossack WS, Nelson HS Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma 2005, 42:257-263.
46. Hauber HP, Gotfried M, Newman K, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 2003, 112:58-63.
47. Bergeron C, Hauber HP, Gotfried M, et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. J Allergy Clin Immunol 2005, 116:983-989.
48. Cohen J, Douma WR, ten Hacken NH, Vonk JM, Oudkerk M, Postma DS Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 2008, 31:1213-1220.
49. Barnes N, Price D, Colice G, et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy 2011, 41:1521-1532.
50. Price D, Thomas M, Haughney J, et al. Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma. Respir Med 2013, 107:987-1000.
51. Colice G, Martin RJ, Israel E, et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J Allergy Clin Immunol 2013, 132:45-54.
52. Price D, Martin RJ, Barnes N, et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010, 126:511-518.
53. Hamid QA, Mak JC, Sheppard MN, Corrin B, Venter JC, Barnes PJ Localization of beta 2-adrenoceptor messenger RNA in human and rat lung using in situ hybridization: correlation with receptor autoradiography. Eur J Pharmacol 1991, 206:133-138.
54. Adcock IM, Gilbey T, Gelder CM, Chung KF, Barnes PJ Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996, 154:771-782.
55. Houghton CM, Langley SJ, Singh SD, et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol 2004, 58:359-366.
56. Scichilone N, Battaglia S, Sorino C, et al. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy 2010, 65:897-902.
57. Corda L, Gardenghi GG, Modina D, Montemurro LT, Novali M, Tantucci C Effects on small airway obstruction of long-term treatments with beclomethasone/formoterol hydrofluoroalkane (metered-dose inhaler) versus fluticasone/salmeterol (dry-powder inhaler) in asthma: a preliminary study. Allergy Asthma Proc 2011, 32:29-34.
58. Vos W, De Backer J, Poli G, et al. Novel functional imaging of changes in small airways of patients treated with extrafine beclomethasone/formoterol. Respiration 2013, 86:393-401.
59. Popov TA, Petrova D, Kralimarkova TZ, et al. Real life clinical study design supporting the effectiveness of extra-fine inhaled beclomethasone/formoterol at the level of small airways of asthmatics. Pulm Pharmacol Ther 2013, 26:624-629.
60. Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009, 103:41-49.
61. Allegra L, Cremonesi G, Girbino G, et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir Med 2012, 106:205-214. for the PRISMA (PRospectIve Study on asthMA control) Study Group.
62. Terzano C, Cremonesi G, Girbino G, et al. 1-year prospective real life monitoring of asthma control and quality of life in Italy. Respir Res 2012, 13:112. for the PRISMA (PRospectIve Study on asthMA control) Study Group.
63. Price D, Small I, Haughney J, et al. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Prim Care Respir J 2013, 22:439-448.